Compared with placebo, rizatriptan does not alleviate symptoms of vestibular migraine attacks at 1 hour and shows minimal ...

Medically reviewed by Smita Patel, DO Migraine headaches are predominantly classified as either migraine without aura or ...

Administration of ubrogepant during the prodromal phase of migraine may alleviate symptoms such as photophobia, phonophobia, and cognitive dysfunction. HealthDay News — Ubrogepant during the ...

Results from a phase 3 clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent preheadache fatigue and light sensitivity ...

Absence of phonophobia occurred in 50.7 and 35.8 percent of events at four hours postdose (odds ratio, 1.97); and at 24 hours post-dose, absence of dizziness occurred in 88.5 and 82.3 percent of ...

phonophobia, and cognitive dysfunction. Led by Peter Goadsby, MBBS, MD, PhD, professor of neurology, King’s College London, London, England, the study was published online on May 12 in Nature ...

After taking the drug or the placebo, the participants were tasked with reporting changes in their symptoms, which included photo- and phonophobia, dizziness, fatigue, neck pain or stiffness, and ...

and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a ...

The matrix highlights strong correlations among symptoms, such as photophobia and phonophobia, which frequently co-occur in migraine patients. Negative correlations are observed in some areas, ...

A rapid review of the existing literature showed that patients valued effectiveness for treating pain more highly than avoiding harm, minimizing cost, or reducing other migraine symptoms such as ...

phonophobia, nausea) two hours after dosing versus placebo, with benefits of pain freedom sustained through 24 and 48 hours for many patients. In the INTERCEPT trial, which treated migraine when ...